|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2007; 49:15-20, doi:10.1016/j.jacc.2006.08.043
(Published online 12 December 2006). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cardiology, University Hospital, Bern, Switzerland.
Manuscript received June 13, 2006; revised manuscript received August 17, 2006, accepted August 21, 2006.
* Reprint requests and correspondence: Dr. Christian Seiler, Professor and Co-Chairman of Cardiology, University Hospital, CH-3010 Bern, Switzerland. (Email: christian.seiler{at}insel.ch).
OBJECTIVES: This study was designed to compare coronary collateral function in patients after bare-metal stent (BMS) or drug-eluting stent (DES) implantation.
BACKGROUND: Drug-eluting stents have an inhibitory effect on the production of cytokines, chemotactic proteins, and growth factors, and may therefore negatively affect coronary collateral growth.
METHODS: A total of 120 patients with long-term stable coronary artery disease (CAD) after stent implantation were included. Both the BMS group and the DES group comprised 60 patients matched for in-stent stenosis severity of the vessel undergoing collateral flow index (CFI) measurement at follow-up and for the duration of follow-up. The primary end point of the investigation was invasively determined coronary collateral function 6 months after stent implantation. Collateral function was assessed by simultaneous aortic, coronary wedge, and central venous pressure measurements (yielding CFI) and by intracoronary electrocardiogram during balloon occlusion.
RESULTS: There were no differences between the groups regarding age, gender, body mass index, frequency of cardiovascular risk factors, use of cardiovascular drugs, severity of CAD, or site of coronary artery stenoses. Despite equal in-stent stenosis severity (46 ± 34% and 45 ± 36%) and equal follow-up duration (6.2 ± 10 months and 6.5 ± 5.4 months), CFI was diminished in the DES versus BMS group (0.154 ± 0.097 vs. 0.224 ± 0.142; p = 0.0049), and the rate of collaterals insufficient to prevent ischemia during occlusion (intracoronary electrocardiographic ST-segment elevation 
0.1 mV) was higher with 50 of 60 patients in the DES group and 33 of 60 patients in the BMS group (p = 0.001).
CONCLUSIONS: Collateral function long after coronary stenting is impaired with DES (sirolimus and paclitaxel) when compared with BMS. Considering the protective nature of collateral vessels, this could lead to more serious cardiac events in the presence of an abrupt coronary occlusion.
| ||||||||||
Related Article
J. Am. Coll. Cardiol. 2007 49: 21-22.
This article has been cited by other articles:
|
|
 |
|
  A. Jabs, S. Gobel, P. Wenzel, A. L. Kleschyov, M. Hortmann, M. Oelze, A. Daiber, and T. Munzel Sirolimus-induced vascular dysfunction increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2130 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Kern Persistent Endothelial Dysfunction After Drug-Eluting Stents: Another Continuing Cost of Reducing Restenosis J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 72 - 73. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Vlaar, B. J. G. L. de Smet, and F. Zijlstra DES or BMS in acute myocardial infarction? Eur. Heart J., November 2, 2007; 28(22): 2693 - 2694. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Windecker and B. Meier Late Coronary Stent Thrombosis Circulation, October 23, 2007; 116(17): 1952 - 1965. [Full Text] [PDF]
|
|
|
|
 |
|
 P.-G. Chassot, A. Delabays, and D. R. Spahn Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction Br. J. Anaesth., September 1, 2007; 99(3): 316 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Meier and C. Seiler Reply J. Am. Coll. Cardiol., August 7, 2007; 50(6): 561 - 561. [Full Text] [PDF]
|
|
|
|
|
|
C. di Mario and K. Dimopoulos The Effect of Drug-Eluting Stents on Collateral Coronary Flow J. Am. Coll. Cardiol., August 7, 2007; 50(6): 560 - 560. [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Parent and S. Rinfret Drug-Eluting Stent Implantation and Coronary Collateral Growth Attenuation: Is Drug the Only Culprit? J. Am. Coll. Cardiol., August 7, 2007; 50(6): 560 - 561. [Full Text] [PDF]
|
|
|
|
|
|
S. Grundmann, N. van Royen, G. Pasterkamp, N. Gonzalez, E. J. Tijsma, J. J. Piek, and I. E. Hoefer A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate Collateral Artery Growth Via Transforming Growth Factor-{beta}1 Release J. Am. Coll. Cardiol., July 24, 2007; 50(4): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boodhwani and F. W. Sellke Reply to the Editor. J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1686 - 1687. [Full Text] [PDF]
|
|
|
|
 |
|
 Another Concern About Drug-Eluting Stents? Journal Watch Cardiology, January 31, 2007; 2007(131): 2 - 2. [Full Text]
|
|
|
|
|
|
M. J. Kern Attenuated Coronary Collateral Function After Drug-Eluting Stent Implantation: A New Downside of Drug-Eluting Stents? J. Am. Coll. Cardiol., January 2, 2007; 49(1): 21 - 22. [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
